Gopten (Trandolapril)

Gopten (trandolapril) is indicated for several cardiovascular conditions where inhibition of the renin‑angiotensin system is beneficial.

• Management of essential hypertension to achieve target blood pressure levels.
• Treatment of chronic heart failure to improve symptoms and reduce hospitalization risk.
• Adjunct therapy after myocardial infarction to limit adverse cardiac remodeling.
• Use in patients with left ventricular dysfunction to support cardiac function.
• May be considered in combination with other antihypertensive agents when monotherapy is insufficient.

Side effects of Gopten vary in frequency; some are relatively common while others are rare but potentially serious.

Common

• Cough.
• Dizziness or light‑headedness, especially after the first dose.
• Headache.
• Fatigue.
• Elevated blood potassium levels.
• Mild rash or itching.

Serious

• Angioedema affecting the face, lips, tongue, or airway.
• Severe hypotension leading to fainting.
• Acute kidney injury indicated by sudden rise in creatinine.
• Liver function abnormalities such as hepatitis.

Before prescribing Gopten, clinicians should evaluate several safety considerations to minimize risk.

• Avoid use in pregnancy; trandolapril is classified as category D and may cause fetal harm.
• Assess renal function; dose adjustment may be required in patients with impaired kidneys.
• Monitor serum potassium and electrolytes, especially when combined with potassium‑sparing diuretics or supplements.
• Caution in patients with a history of angioedema or hereditary angioedema.
• Evaluate for hypotension, particularly in volume‑depleted individuals or those on diuretics.
• Use carefully in elderly patients due to increased sensitivity to blood‑pressure lowering effects.

Gopten can interact with other medicines; some combinations should be avoided while others require close monitoring.

Avoid

• Concurrent use with other ACE inhibitors, ARBs, or direct renin inhibitors due to additive risk of hyperkalaemia and renal impairment.
• Co‑administration with aliskiren in patients with diabetes or renal dysfunction.
• Use with potassium supplements or potassium‑sparing diuretics without monitoring serum potassium.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) which may reduce antihypertensive efficacy and affect kidney function.
• Diuretics, especially loop or thiazide types, which can increase the risk of hypotension.
• Lithium, as trandolapril may raise lithium concentrations and precipitate toxicity.
• Certain antidiabetic agents, where blood‑glucose control may be altered.